Leslie confirms in the attached video that she is to meet with the U.S FDA next month. To those who doubted the rationale about last years CR to raise funds to purchase the OSU and Mayo Clinic IP and take control over those vaccines currently undergoing trials, can you imagine what FDA approval to fast track the next phase trials would do to the share price?
Would certainly justify the strategy that Paul Hopper & Leslie have been slowly and deliberately putting in place over the past 18 months.
2019 is going to be transformative for this company. Truly exciting times for all shareholders!
IMU Price at posting:
2.0¢ Sentiment: Hold Disclosure: Held
